Adaptive Biotechnologies (NASDAQ:ADPT) is a biotechnology company specializing in immune-driven medicine through high-resolution sequencing and analysis of the adaptive immune system. The company’s core business revolves around its proprietary immunoSEQ® platform, which profiles T‐cell and B‐cell receptors to uncover immune signatures associated with disease. By leveraging deep sequencing, bioinformatics, and machine learning, Adaptive Biotechnologies aims to develop both diagnostic and therapeutic products that harness the power of the body’s immune response.
Key products and services include the immunoSEQ® assay, which enables researchers and clinicians to measure immune repertoire diversity and track minimal residual disease in hematologic cancers. The T-Detect™ line of diagnostic tests uses proprietary algorithms to identify T-cell responses indicative of infectious diseases, autoimmune disorders, and oncology indications. In collaboration with leading pharmaceutical and research institutions, the company also deploys its T-Cell Receptor (TCR) Antigen Map™ to match specific immune receptors with their target antigens, supporting the discovery and optimization of next-generation therapies.
Founded in 2009 as a spin-out from the Fred Hutchinson Cancer Research Center in Seattle, Adaptive Biotechnologies has grown under the leadership of co-founders Chad Robins (Chief Executive Officer) and Harlan Robins (Chief Scientific Officer). From its early focus on immune repertoire profiling, the company has advanced into translational applications, filing numerous patent applications and publishing peer-reviewed research. Its management team also includes executives from genomics, diagnostics and life sciences industries, reinforcing its strategic direction toward precision immunology.
Headquartered in Seattle, Washington, Adaptive Biotechnologies operates CLIA-certified laboratories and maintains strategic partnerships across North America, Europe and the Asia-Pacific region. Through collaborations with pharmaceutical companies, academic institutions and healthcare providers, the company continues to expand its global footprint and accelerate the development of immune-based diagnostics and therapies aimed at improving patient outcomes in oncology, infectious disease and beyond.